Hemophilia B: all 275 studies

Page 3 of 3. Open to participants first (52), then studies with results posted, then the rest; newest registration first within each.

• Thrombin Generation Numerical Models Validation in Haemophilic CaseCompletedNCT02300519
• A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 YearsCompletedNCT02263469Phase 3
• A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia BCompletedNCT02263456Phase 3
• An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing SurgeryCompletedNCT02250573Phase 3
• A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.CompletedNCT02250560Phase 3
• To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily LivesCompletedNCT02241694
• An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B PatientsCompletedNCT02231944Phase 3
• Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBISCompletedNCT02190149
• Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male SubjectsWithdrawnNCT02084810Phase 1
• Web-based Application for the Population Pharmacokinetic Service - Phase 1CompletedNCT02061072
• Global Hemostatic Methods in Hemophilia and Von Willebrand's DiseaseStatus unknownNCT02061033
• A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia CareCompletedNCT02049099
• Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia BWithdrawnNCT02048111Phase 3
• A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B PatientsCompletedNCT02035605Phase 1
• Impact of Pain on Functional Impairment and Quality of Life in Adults With HemophiliaCompletedNCT01988532
• Project to Update the Study of Congenital Haemophilia in SpainCompletedNCT01959555
• A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without InhibitorsCompletedNCT01949792Phase 1
• Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without InhibitorsCompletedNCT01921855Phase 1
• A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With InhibitorsCompletedNCT01830712
• Viscosupplementation in Patients With Hemophilic ArthropathyCompletedNCT01748201Phase 4
• Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia BActive, not recruitingNCT01687608Phase 1/2
• A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150CompletedNCT01625390Phase 2/3
• Hemophilia B Gene Therapy With AAV8 VectorTerminatedNCT01620801Phase 1
• Study on Von Willebrand Disease and Hemophilia in Cuenca, EcuadorCompletedNCT01589848
• Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With InhibitorsCompletedNCT01586936
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing SurgeryCompletedNCT01579968
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical PracticeCompletedNCT01579955
• Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy VolunteersCompletedNCT01563471Phase 1
• Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding StateCompletedNCT01562587Phase 1
• Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding StateCompletedNCT01562457Phase 1
• Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of ThromboelastographyCompletedNCT01561924Phase 1
• Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedNCT01561417Phase 1
• Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedNCT01561391Phase 4
• Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese SubjectsCompletedNCT01555749Phase 1
• Socialization of Adult Men With Congenital Hemophilia A or BCompletedNCT01510418
• Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing CountriesCompletedNCT01503567
• Osteoporosis and MRI Study in HemophiliaTerminatedNCT01460147Not applicable
• Survey Evaluating the Psychosocial Effects of Living With HaemophiliaCompletedNCT01322620
• Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B PatientsCompletedNCT01288391Phase 1
• Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male SubjectsCompletedNCT01272206Phase 1
• Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and InhibitorsCompletedNCT01234545
• Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia BCompletedNCT01233440Phase 1
• Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or BCompletedNCT01228669Phase 1
• Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or BCompletedNCT01220141
• Comparing the Burden of Illness of Hemophilia in the Developing and the Developed WorldCompletedNCT01217255
• IMMUNINE Pre-Treatment StudyCompletedNCT01128881Phase 4
• Correlation Between Vitamin D Status and Bone Mineral Density in Patients With HemophiliaCompletedNCT01090206Not applicable
• Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia BCompletedNCT00979238Phase 1
• Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia BCompletedNCT00956345Phase 1
• A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male VolunteersCompletedNCT00951873Phase 1
• Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With InhibitorsCompletedNCT00951405Phase 2
• Females With Severe or Moderate Hemophilia A or B: A Multi-Center StudyCompletedNCT00936845
• Females With Severe or Moderate Hemophilia A or B: an International Multi-center StudyCompletedNCT00936312
• Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and BCompletedNCT00922792Phase 1
• Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia DatabaseCompletedNCT00853086
• Gait Evaluation in Haemophiliac PatientsCompletedNCT00824798
• Phase I/IIa Study of FIXFc in Hemophilia B PatientsCompletedNCT00716716Phase 1
• Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IXCompletedNCT00710619
• Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle ArthropathyCompletedNCT00638001Phase 4
• Study Evaluating Approach to Treatment of Haemophilia A and B in SpainCompletedNCT00581438
• Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia BCompletedNCT00581126Phase 4
• High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With InhibitorsCompletedNCT00571584Phase 4
• LTFU for Gene Transfer Subjects With Hemophilia BCompletedNCT00515710
• Study Evaluating Allergic Reactions To Benefix In Hemophilia B PatientsCompletedNCT00244114
• The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding LogsCompletedNCT00212459Not applicable
• Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia BCompletedNCT00195221
• Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual UseCompletedNCT00167973
• Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)CompletedNCT00139828Phase 4
• Trial of NovoSeven® in Haemophilia - Joint BleedsCompletedNCT00108797Phase 4
• Efficacy of NovoSeven® in Bleeding Prophylaxis in HemophiliaCompletedNCT00108758Phase 2
• Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia BCompletedNCT00093210Phase 3
• Study Evaluating rFIX; BeneFIX® in Hemophilia BCompletedNCT00093171Phase 3
• Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia BTerminatedNCT00076557Phase 1/2
• Study Evaluating rFIX; BeneFIX in Severe Hemophilia BCompletedNCT00037557Phase 3
• Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX DeficiencyCompletedNCT00004801Phase 1/2

← Hemophilia B overview